Primary malignant neoplasm of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Furthermore, elevation of PD-L1 expression on TC after neoadjuvant chemotherapy was associated with reduced chemotherapy response and inferior progression-free survival in patients with lung cancer.
|
31145232 |
2020 |
Primary malignant neoplasm of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
The evaluation of Programmed cell Death Ligand 1 (PD-L1) expression in the tumor cells with immunohistochemistry is a mandatory diagnostic step in the treatment of lung cancer.
|
31809311 |
2020 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Besides being a predictive biomarker of response to immunotherapy in lung cancer in general, programmed death-ligand 1 (PD-L1) is not so well correlated with treatment outcomes of lung adenocarcinoma (ADC) harbouring epidermal growth factor receptor (EGFR) mutations, as reported studies are inconclusive and seldom addressed the issues of response to treatment and resistance.
|
31760310 |
2020 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
These results demonstrated that tumor-infiltrating TAMs are extrinsic regulators of tumor PD-L1 expression, indicating that combination therapy targeting both tumor PD-L1 and stromal TAMs might be a possible strategy for effective treatment of lung cancer.
|
31821665 |
2020 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Lymphovascular Invasion Is Associated with Mutational Burden and PD-L1 in Resected Lung Cancer.
|
31550464 |
2020 |
Primary malignant neoplasm of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We then examined the effects of CAFs isolated from lung cancer tissues on programmed death ligand 1 (PD-L1) expression in lung adenocarcinoma cell lines.
|
31462002 |
2019 |
Primary malignant neoplasm of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
We also confirmed the up-regulation of PD-L1 by cisplatin, at both RNA and protein levels, in nude and immunocompetent mice bearing tumors grafted with A549, LNM-R, or LLC1 lung cancer cell lines.
|
31404614 |
2019 |
Primary malignant neoplasm of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
EGFR-TKI resistance promotes immune escape in lung cancer via increased PD-L1 expression.
|
31747941 |
2019 |
Primary malignant neoplasm of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
A significant positive correlation between MET and PD-L1 expression in lung cancer was determined in an analysis based on The Cancer Genome Atlas (TCGA) and in an immunohistochemistry study.
|
31480591 |
2019 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
We performed the meta-analysis to evaluate the overall safety of programmed cell death-1 (PD-1) or ligand 1 (PD-L1) inhibitor treatment for lung cancer patients.
|
31348245 |
2019 |
Primary malignant neoplasm of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Here, we assessed the tumor cell numbers and PD-L1 expression for Cryo with EBUS-GS for PPLs and TBB in patients with lung cancer.
|
31420048 |
2019 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Overall, our work shows the rationale for the treatment of lung cancer with a combination of PD-1/PD-L1 blockade and low-dose apatinib.
|
30755403 |
2019 |
Primary malignant neoplasm of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
In addition, PD-L1 is also expressed on a wide range of tumor cells, including lung cancer, breast cancer and melanoma.
|
31612048 |
2019 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
We aimed to compare intra- and extracranial responses to immune checkpoint inhibitors (ICIs) in lung cancer with brain metastases (BM), and to explore tumor microenvironments of the brain and lungs focusing on the programmed cell death-1 (PD-1)/programmed cell death ligand-1 (PD-L1) pathway.
|
30616523 |
2019 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
The percentage of programmed death ligand 1 (PD-L1) positivity in cancer cells, named as the tumor proportion score, is considered to be a predictive biomarker for anti-PD-1/PD-L1 therapy in lung cancer.
|
31294893 |
2019 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Programmed death-ligand 1 (PD-L1) is a crucial target for lung cancer immunotherapy.
|
31741753 |
2019 |
Primary malignant neoplasm of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
Knowledge regarding programmed death-ligand 1 (PD-L1) expression in lung cancer is limited.
|
30282880 |
2019 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
With the pathway inhibitors, we found ERK1/2 pathway involved in inducing PD-L1 in resistant lung cancer.
|
30842489 |
2019 |
Primary malignant neoplasm of lung
|
0.100 |
GeneticVariation
|
disease |
BEFREE |
In combination with anti-PD-1 inhibitors, pegilodecakin increased the responses in RCC and lung cancer with efficacy agnostic to PD-L1 status and tumor mutational burden.
|
30790069 |
2019 |
Primary malignant neoplasm of lung
|
0.100 |
AlteredExpression
|
disease |
BEFREE |
To the best of our knowledge, this study is the largest to evaluate the association between PD-L1 expression and clinicopathological and molecular features in lung cancer with a highly prevalent <i>EGFR</i> mutation.
|
31561631 |
2019 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Exploring a Tumor-Intrinsic PD-L1 Signal with Proximity-Dependent Biotin Identification in Lung Cancer Cells.
|
31021072 |
2019 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Monoclonal antibodies targeting programmed death-1 receptor (PD-1) and its ligand (PD-L1) have been developed to treat cancers including lung cancer.
|
30948928 |
2019 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
On the other hand, LKB1 deficiency can promote an immunosuppressive microenvironment and may be involved in primary resistance to anti-PD-1/anti-PD-L1, as it has been reported in lung cancer.
|
30995715 |
2019 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
Neutralizing antibodies targeting immune checkpoint programmed cell death protein 1 (PD-1) or its ligand (PD-L1) have been particularly successful for tumor types with limited therapeutic options such as melanoma and lung cancer.
|
31031765 |
2019 |
Primary malignant neoplasm of lung
|
0.100 |
Biomarker
|
disease |
BEFREE |
AhR inhibitors exert significant antitumor activity and synergize with anti-PD-L1 antibody in lung cancer mouse models.
|
30850589 |
2019 |